SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 13.97 |
| Enterprise Value ($M) | 3.93 |
| Book Value ($M) | 12.04 |
| Book Value / Share | 3.65 |
| Price / Book | 1.16 |
| NCAV ($M) | 9.80 |
| NCAV / Share | 2.97 |
| Price / NCAV | 1.43 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.33 |
| Return on Assets (ROA) | -4.68 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.35 |
| Current Ratio | 7.35 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 11.34 |
| Assets | 13.58 |
| Liabilities | 1.54 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Lind Global Fund II LP | 3.10 | -64.92 | |
| 13D/A | Werth Peter J. | 4.51 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 26,165 | 75,883 | 34.48 | |
| 17,740 | 46,909 | 37.82 | |
| 46,933 | 138,285 | 33.94 | |
| 38,519 | 130,207 | 29.58 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CELU – Celularity Inc. | CELZ – Creative Medical Technology Holdings, Inc. |
| CGEN – Compugen Ltd. | CKPT – Checkpoint Therapeutics, Inc. |
| CLDX – Celldex Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io